Need more? Try out  Advanced Search (20+ criteria)»


Last Update

This profile was last updated on 5/2/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Della Matheson?

Della Lorraine Matheson

Trial Coordinator

University of Miami

HQ Phone:  (305) 421-4000

Direct Phone: (305) ***-****direct phone


+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.


  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

University of Miami


Key Biscayne, Florida,33149

United States

Company Description

The University of Miami is a vibrant community of exceptionally talented individuals engaged in the pursuit of academic excellence, the discovery of new knowledge, and service to the region and beyond. More than 15,600 undergraduate and graduate students from... more

Find other employees at this company (35,000)

Background Information

Employment History

Research Coordinator

The Diabetes Foundation of Mississippi Inc

Web References(29 Total References)

Dialogue Diabetes Fall 2000 [cached]

By Della Matheson, R.N., C.D.E., Trial Coordinator, DPT-1, University of MiamiWe would like to invite all those who are eligible to participate in this exciting research to contact Della Matheson, R.N., C.D.E., at 305-243-3781. [cached]

The nationwide launch of The Diabetes Prevention Trial – Type 1 (DPT-1) marked a new era in the research that will advance scientific progress toward this remarkable goal, according to Della Matheson, RN, CDE, Trial Coordinator for the study at the University of Miami.There are approximately one million Americans living with this disease and another 30, 000 children and young adults newly diagnosed every year.Despite huge improvements in the care and treatment of Type 1 Diabetes in the past twenty years, this disease remains the leading cause of blindness, kidney failure, and amputations in America.The cost of diabetes to individuals and to the public measures in billions of dollars annually with an immeasurable cost to the quality of life in those affected with this serious disease.Although research for a cure remains at the forefront for the children of today who have Diabetes, it is equally as important for the children of tomorrow that prevention of this life-threatening disease becomes a reality, added Ms. Matheson.Type 1 (insulin dependent) Diabetes is an autoimmune disease that usually occurs in childhood or young adulthood.By autoimmune, we mean that the persons own immune system has been triggered to destroy its own tissue.In the case of Type 1 (insulin dependent) Diabetes, the body has attacked and destroyed the insulin producing cells, known as islet cells. Without islet cells, the body no longer makes insulin and Type 1 Diabetes occurs.Destruction of the cells is gradual and most symptoms of diabetes do not begin until almost all insulin-producing cells are destroyed.Most people do not realize they are developing diabetes until the damage is complete.Of those 2, 985 have been found to have the Islet Cell Antibodies, explained Ms. Matheson.Once the antibody is found, we invite the participants to come in for further testing that will actually measure their degree of risk, added the nurse coordinator for the University of Miami study.These tests include the measurement of additional antibody activity, genetic testing that may influence risk for development of diabetes, and tests that measure the amount of insulin the person is currently able to produce.With the results of these staging tests, the researchers can determine if the person is at low risk, moderate risk, or high risk for developing diabetes over the next five years.Those at Moderate Risk (25-50 % risk for development over the next five years) and those at High Risk (greater than 50 % risk for development over the next five years) are asked if they want to participate in research to see if the development of diabetes can be prevented.Almost all type 1 Diabetics developed their disease before the age of 40 and need to take daily insulin injections.If you wish to speak to one of the Trial Coordinators in Florida, you can call either Della Matheson, RN at the University of Miami (305-243-3781) or Mary Alice Dennis, RN (352-392-7836) at the University of Florida.As a reminder, this information should not be relied on as medical advice and is not intended to replace the advice of your child's pediatrician.Please read our full disclaimer.

IntelliQuest Media: The next best thing to being there

Della Matheson, RN, CDE Jennifer Marks, MD, FACP, FACE
Product Number: 201118130

Press Releases: New Directors Join Board [cached]

Della Matheson, R.N., C.D.E.
Della Matheson, R.N., C.D.E.

"Every meal is a mathematical formula," said Della Matheson, another conference speaker.
Matheson, a trial coordinator for the University of Miami Clinical Center for Type 1 diabetes TrialNet, will give an update on diabetes research at the conference. "The process that leads to Type 1 diabetes we know begins long before the person actually gets the disease," Matheson said. Matheson emphasizes that Type 1 diabetes is an autoimmune disease, making the research on stem cell replacement so critical. When she first began researching ways to eradicate Type 1 diabetes, she thought her team would be able to identify the key risk factors and correct them, preventing the disease. But the process became more daunting than she realized. "For every little onion skin you peel back with answering one question, it leads to another. The immune system is extremely complex," Matheson said. "It's important for people to understand the research is going on, how collaborative it is, how many people are working on it, and really how far we've come." One recent advancement, Matheson explained, came when scientists discovered the liver was not the best site to implant beta cells, the cells that produce insulin. Instead, they began implanting them in the fatty layer of the patients' abdomen, which is less potentially dangerous. Matheson said having Type 1 diabetes makes her sensitive to how solutions and cures are reported in the media. When she was diagnosed nearly 35 years ago, doctors told her there would be a cure in 10 years. "We're launching into a new era of looking at the issue in a more complex way to stop the autoimmune process," Matheson said.

Similar Profiles


Browse ZoomInfo's Business
Contact Directory by City


Browse ZoomInfo's
Business People Directory


Browse ZoomInfo's
Advanced Company Directory